- Home
- VNOM vs GRFS Comparison
VNOM vs GRFS Comparison
Compare VNOM & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | GRFS |
|---|---|---|
| Founded | 2013 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.0B |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | VNOM | GRFS |
|---|---|---|
| Price | $38.36 | $9.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 2 |
| Target Price | ★ $53.36 | $10.15 |
| AVG Volume (30 Days) | ★ 1.8M | 546.9K |
| Earning Date | 11-03-2025 | 01-01-0001 |
| Dividend Yield | ★ 6.30% | 1.58% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.93 | 0.64 |
| Revenue | $1,131,200,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $56.75 | $5.46 |
| Revenue Next Year | $27.17 | $5.60 |
| P/E Ratio | $19.67 | ★ $17.78 |
| Revenue Growth | ★ 42.38 | 7.31 |
| 52 Week Low | $34.71 | $6.19 |
| 52 Week High | $52.10 | $11.14 |
Technical Indicators
Market Signals| Indicator | VNOM | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 55.84 |
| Support Level | $37.70 | $8.69 |
| Resistance Level | $39.49 | $9.22 |
| Average True Range (ATR) | 1.17 | 0.19 |
| MACD | -0.22 | 0.04 |
| Stochastic Oscillator | 18.11 | 79.52 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.